Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norursodeoxycholic Acid in NASH
NCT05083390Phase 2Recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Jul 2019
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of norursodeoxycholic acid in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Proportion of participants with resolution of NASH and no worsening of fibrosis at 72 weeks. Started Jul 2019; status: recruiting.
02
Drugs
norursodeoxycholic acid
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05083390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083390.